RxDoctor Payments DataLook up a doctor →

John Southard, MD

Pulmonary Disease · Council Bluffs, IANPI 1104967090

Payments from drug & device makers

$245,196in general payments, 2019–2025

Across 816 payments — averaging $300.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$139K
  • Shionogi Inc$41K
  • Mylan Specialty L.p.$35K
  • AstraZeneca$11K
  • Chiesi USA, Inc.$9K
  • Viatris Specialty LLC$4K
  • plus $6K from 41 others

What the payments were for

  • Consulting fees$13,2517%
  • Speaking & faculty fees$150,63682%
  • Travel & lodging$7,3334%
  • Food & beverage$12,2777%
  • Education$4300%
  • Entertainment$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$245,196 in reported general payments places this provider in the 90th percentile of 110 pulmonary disease providers in Iowa.

See all pulmonary disease providers in Iowa

Medicare billing

Part B allowed, 2024
$174,529
Medicare patients
516
Services billed
7,305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter753$571,280
Aralast NpAlpha-1-Proteinase Inhibitor13$349,019
OfevNintedanib Esylate24$296,853
Breo ElliptaFluticasone/Vilanterol284$134,756
Dupixent PenDupilumab31$130,391
Breztri AerosphereBudesonide/Glycopyr/Formoterol126$92,354
Dupixent SyringeDupilumab21$85,574
Prolastin CAlpha-1-Proteinase Inhibitor12$75,337
Pirfenidone35$58,878
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr67$46,821
DelstrigoDoravirine/Lamivu/Tenofov Diso11$28,603
Stiolto RespimatTiotropium Br/Olodaterol Hcl31$19,163
Spiriva RespimatTiotropium Bromide14$13,104
Incruse ElliptaUmeclidinium Bromide26$12,002
Epinephrine52$8,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$138,754$770,9961,151 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$613$329,12069 claims
AstraZenecaBreztri Aerosphere, Symbicort$11,272$98,679154 claims
Grifols USA, LLCProlastin C$250$75,33712 claims
MerckDelstrigo$113$28,60311 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$30$3412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 110 pulmonary disease providers in Iowa.

Other pulmonary disease in Council Bluffs

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →